The purchase will help BioLife expand its cell and gene therapy portfolio, the company said. Sexton's bioproduction portfolio consists of closed vials for cell therapy, final-dose packaging, human platelet lysate media, and automated cell processing machines, according to BioLife. Sexton was spun off from Cook Regentec in 2019.

All of Sexton Biotechnologies' staff will remain with the company, and it will continue operations at its Indianapolis, IN, headquarters. The purchase will close by September 1, BioLife said.

BioLife Solutions launches freezer for cell and gene therapy developers
BioLife Solutions has launched a new line of high-capacity, controlled-rate freezers with a focus on the cell and gene therapy industry.

Sexton collaborates to improve flexible automation
Sexton Biotechnologies has formed a partnership with Hitech Health and Med Institute covering flexible automation for cell and gene therapy manufacturers.

BioLife Solutions invests in cell and gene therapy products
BioLife Solutions, a supplier of cell and gene therapy bioproduction tools, along with innovation accelerator partner Casdin Capital, have invested in...

Sexton, BioSpherix collaborate to support cell & gene therapy needs
Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.